TABLE 6.
Dual Stain Triage of HPV-Positive NILM, ASC-US, or LSIL Cytology Results in a Cotesting Setting in STRIDESa
| Current test result | N | % of Total | CIN3+ cases | CIN3+ immediate risk (%) |
Clinical management recommendation |
|---|---|---|---|---|---|
| HPV+/NILM/DS+ | 332 | 3.3 | 7 | Follow-up still underway | |
| HPV+/NILM/DS− | 929 | 9.2 | 5 | Follow-up still underway | |
| HPV+/ASC-US/ DS+ | 145 | 1.4 | 11 | 7.5 | Colposcopy |
| HPV+/ASC-US/ DS− | 95 | 0.9 | 1 | 1.1 | 1-y return |
| HPV+/LSIL/DS+ | 150 | 1.5 | 12 | 8.0 | Colposcopy |
| HPV+/LSIL/DS− | 68 | 0.7 | 0 | 0.0 | 1-y return |
aDuration of follow-up in the STRIDES cohort is currently not sufficient to estimate risks associated with NILM/DS+, cumulative 3-year risks, and management confidence probabilities; follow-up is ongoing.